Related Experiment Video

Updated: Aug 8, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone

Chih-Jung Yao1, Gi-Ming Lai, Chin-Feng Chan

  • 1Division of Cancer Research, National Health Research Institutes, Taipei, Taiwan.

International Journal of Cancer
|August 12, 2005
PubMed

Insights

Lovastatin and troglitazone show dramatic synergistic anticancer effects. This combination enhances cell cycle regulation, offering a promising new cancer therapy regimen.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Lovastatin (HMG-CoA reductase inhibitor) and troglitazone (PPAR-gamma agonist) have shown limited efficacy alone in cancer treatment.
  • Previous combinations of these drugs with other agents yielded varied outcomes.
  • There is a need for improved therapeutic strategies for cancer.

Purpose of the Study:

  • To investigate the potential synergistic anticancer effects of combining lovastatin and troglitazone.
  • To explore the molecular mechanisms underlying this potential synergism.
  • To evaluate the efficacy of this combination in various cancer cell lines.

Main Methods:

  • Testing the combination of lovastatin and troglitazone on a wide range of cancer cell lines.
  • Analyzing the effects on cell cycle regulatory proteins, including E2F-1, p27(Kip1), CDK2, cyclin A, and RB phosphorylation.
  • Assessing anticancer activity at clinically achievable drug concentrations.

Main Results:

  • A dramatic synergistic anticancer effect was observed between lovastatin and troglitazone in most tested cell lines.
  • This synergism was associated with coordinated modulation of E2F-1 and p27(Kip1).
  • Significant alterations in cell cycle regulators like CDK2, cyclin A, and RB phosphorylation were noted.

Conclusions:

  • The combination of lovastatin and troglitazone demonstrates significant synergistic anticancer activity.
  • This combination effectively targets key cell cycle regulatory pathways.
  • This drug combination represents a promising future therapeutic strategy for cancer treatment.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...